Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
Article Details
- CitationCopy to clipboard
Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. Epub 2006 Dec 15.
- PubMed ID
- 17172449 [ View in PubMed]
- Abstract
Although phosphoinositide 3-kinases (PI3Ks) play beneficial pro-cell survival roles during tissue ischemia, some isoforms (gamma and delta) paradoxically contribute to the inflammation that damages these same tissues upon reperfusion. We therefore considered the possibility that selectively inhibiting proinflammatory PI3K isoforms during the reperfusion phase could ultimately limit overall tissue damage seen in ischemia/reperfusion injuries such as myocardial infarction. Panreactive and isoform-restricted PI3K inhibitors were identified by screening a novel chemical family; molecular modeling studies attributed isoform specificity based on rotational freedom of substituent groups. One compound (TG100-115) identified as a selective PI3K gamma/delta inhibitor potently inhibited edema and inflammation in response to multiple mediators known to participate in myocardial infarction, including vascular endothelial growth factor and platelet-activating factor; by contrast, endothelial cell mitogenesis, a repair process important to tissue survival after ischemic damage, was not disrupted. In rigorous animal MI models, TG100-115 provided potent cardioprotection, reducing infarct development and preserving myocardial function. Importantly, this was achieved when dosing well after myocardial reperfusion (up to 3 h after), the same time period when patients are most accessible for therapeutic intervention. In conclusion, by targeting pathologic events occurring relatively late in myocardial damage, we have identified a potential means of addressing an elusive clinical goal: meaningful cardioprotection in the postreperfusion time period.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) LY-294002 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform IC 50 (nM) 7300 7.4 22 Details Wortmannin Phosphatidylinositol 3-kinase regulatory subunit alpha IC 50 (nM) 147000000 7.4 22 Details Wortmannin Phosphatidylinositol 3-kinase regulatory subunit alpha IC 50 (nM) 103 7.4 22 Details Wortmannin Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform IC 50 (nM) 99 7.4 22 Details Wortmannin Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform IC 50 (nM) 55 7.4 22 Details